课题基金 / 基金详情

The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) Trial

The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) Trial
房颤导管消融 (OCEAN) 试验后高危患者的最佳抗凝治疗
批准号：
419276
负责人：
Verma Atul
金额：
$69.66万
依托单位：
Ottawa Heart Institute Research Corporation (Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
未结题
起止时间：
2020-03-01 至 2025-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=419276&lang=en
关键词：
Atrial Fibrillation Catheter Ablation Oral Anticoagulation Randomized Clinical Trial Stroke Prevention

项目摘要

项目成果

Verma Atul的其他基金

相似基金

相关文献

中文摘要
翻译
这项试验正在比较预防中风的医学方法，这些方法适用于患有房颤(AF)但已经接受了称为消融的成功手术以消除或大幅减少心律失常的人。AF通常与I相关联
英文摘要
This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) but have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia. AF is normally associated with an i
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) Trial
海外基金